Sarcoma: A Plain-Language Overview

The World Health Organization lists more than 100 separate tumor types under the sarcoma heading. That count is from its 2020 update. Two people can both be told they have sarcoma. They may still face different drugs, different surgery, and different odds.

Soft tissue sarcoma is the larger group. For 2025 the American Cancer Society projected 13,520 new cases and 5,410 deaths in the United States, and the National Cancer Institute's PDQ summary carries that projection as its opening figure. In adults these tumors start in the limbs 45% of the time, inside the abdomen 38%, on the trunk 10%, and in the head and neck 5%.

Bone sarcomas are counted separately and skew much younger. Osteosarcoma is the most common bone sarcoma. It occurs at about 5.4 cases per million each year in ages 0 to 19. That is roughly 440 cases a year in that age group in the US. More than half of those tumors in children and teens arise in the long bones around the knee.

So the first useful question is not "how bad is it" but "which one is it," in the exact words the pathologist used.

This is the part of sarcoma care that goes wrong most often, and it goes wrong early.

Sometimes a general surgeon removes a lump, assuming it is harmless. It turns out to be sarcoma. That is called an unplanned excision. It spreads tumor cells through tissue layers that a sarcoma surgeon would have taken out in one block. The NCI cites a drop in local recurrence from 45% to 18%. The 45% is for people never referred. The 18% is for people who reached a specialist center before surgery.

The advised first step is an image-guided core-needle biopsy. If a needle cannot reach the mass, or gives no answer, a planned incisional biopsy is used instead. The needle track is planned too, because it must be cut out later with the tumor. So the surgeon, the radiation oncologist, and the radiologist all agree before anyone touches the mass.

Two phrases in a pathology or operative report signal trouble: cutting into the tumor, and shelling out gross tumor. Both raise the chance of local recurrence.

Ask for referral to a sarcoma center before a biopsy, not after. That applies to any deep mass, any mass larger than 5 cm, and any mass that is growing.

Most soft tissue sarcomas are graded by the FNCLCC system. It adds up three separate scores.

Differentiation scores 1 to 3. It rates how much the tissue still looks like the normal tissue it came from. Mitotic count is how many cells are caught dividing. It scores 1 for 0 to 9 per 10 high-power microscope fields, 2 for 10 to 19, and 3 for 20 or more. Tumor necrosis, meaning dead tissue inside the tumor, scores 0 for none, 1 for under 50%, and 2 for 50% or more.

The three add up. A total of 2 or 3 is grade 1, a total of 4 or 5 is grade 2, and a total of 6 to 8 is grade 3. Ask which of the three drove your grade. A high mitotic count and heavy necrosis mean different things to the team.

AJCC staging joins TNM with the FNCLCC grade. The size cutoffs change by body site.

For the limbs and trunk, T1 is 5 cm or less and T4 is larger than 15 cm. For head and neck sarcomas, T1 is 2 cm or less and T3 is larger than 4 cm. For abdominal and visceral sarcomas, T1 means the tumor is confined to the organ. A 6 cm tumor is therefore staged differently in a thigh than in a cheek.

MRI or CT covers the main tumor. A chest CT is standard too, above all for high-grade tumors. The lung is where sarcoma spreads most often.

Some subtypes get extra imaging. Myxoid and round cell liposarcomas get abdominal and pelvic CT, because they spread to unusual soft tissue sites. Angiosarcoma, epithelioid sarcoma, and alveolar soft part sarcoma get brain imaging. They reach the brain and spinal cord more often than other sarcomas.

Surgery is the backbone. The goal is a negative margin, meaning no tumor cells at the cut edge under the microscope. For a small, low-grade tumor of 5 cm or less, NCI describes surgical excision with clear margins of 1 cm to 2 cm or more as the treatment of choice, and chemotherapy is usually not given. Radiation may still be added if wide margins cannot be obtained.

When radiation is added, the debate is before or after surgery. Preoperative radiation uses about 50 Gy to a wide field with a 16 to 20 Gy boost. Postoperative radiation uses about 45 Gy with an 18 Gy boost. Radiation first causes more wound healing problems, 35% versus 17%. Five-year local control is about the same either way, near 93%. Radiation lowers local recurrence in both orders. It does not improve overall survival.

The core drugs are doxorubicin and ifosfamide, both given by vein at amounts your oncologist scales to body size, kidney function and how well you tolerated the last cycle. Pooled trial data show chemotherapy cuts overall mortality by 6% in absolute terms. For doxorubicin plus ifosfamide the figure is about 11%.

Those numbers are real but small. That is why the choice is individual. Later-line options include gemcitabine with docetaxel, trabectedin, eribulin, pazopanib, and dacarbazine.

Gastrointestinal stromal tumor (GIST) is the clearest example. About 85% carry a driver change in the KIT or PDGFRA gene. About 95% stain positive for CD117. A stain called DOG1 finds the ones that do not. Treatment is imatinib, usually 400 mg a day on the label, running at least a year after surgery and 3 years for high-risk disease. Go by your own bottle rather than that figure: the strength you are prescribed is set by your sarcoma team and is often adjusted. Tumours with a KIT exon 9 change may do better on double the usual amount. Which figure applies to you is a decision for your sarcoma team, based on your mutation and how you tolerate it — check your own prescription rather than this paragraph. Tumors with the PDGFRA D842V change do not respond to imatinib at all. They are treated with avapritinib. Sunitinib, regorafenib, and ripretinib follow if resistance develops.

Osteosarcoma runs a different sequence: chemotherapy first, then surgery. The drugs are doxorubicin, cisplatin, and high-dose methotrexate, and the surgery is limb-sparing where possible. The pathologist then measures how much tumor the chemotherapy killed. At least 90% necrosis in the resected specimen predicts a better outcome. In the international EURAMOS trial, people whose disease was localized at diagnosis and completely resected had five-year overall survival of about 79%.

• The exact WHO subtype name from the pathology report, not just "sarcoma"
• The FNCLCC grade and all three component scores
• Whether a sarcoma pathologist has reviewed the slides
• Whether the biopsy tract is documented so it can be excised with the tumor
• Whether a chest CT has been done
• Which sarcoma center will review the case, and when

• Call 911 or go to an emergency department if back or bone pain comes with new leg weakness, numbness, or loss of control of urine or stool. A tumor pressing on the spinal cord has to be treated within hours to protect nerves. Do the same if a bone gives way, bends, or cannot take weight after a minor knock or no injury, which can be a break through weakened bone.
• Call your care team right away, day or night, if you have a fever of 100.4°F (38°C) or higher, or shaking chills, while you are on chemotherapy. Fever during chemotherapy is a medical emergency, because an infection can move fast while white cells are low. If no one picks up quickly, go to an emergency department and say at once that you are on chemotherapy.
• Call your care team the same day if a lump becomes hot, red, or suddenly bigger, if you are short of breath or coughing blood, or if pain that was controlled stops responding to your usual medicine.
• Call your care team within a day or two if a wound is slow to heal or is leaking, or if numbness, swelling, or weakness in a treated limb is getting worse.

https://www.cancer.gov/types/soft-tissue-sarcoma/hp/adult-soft-tissue-treatment-pdq https://www.cdc.gov/cancer-preventing-infections/patients/fever.html https://www.cancer.gov/types/bone/hp/osteosarcoma-treatment-pdq https://www.cancer.gov/types/soft-tissue-sarcoma/hp/gist-treatment-pdq https://www.cancer.org/research/cancer-facts-statistics.html